Anti-Viral Central Memory CD8 Veto Cells is under clinical development by Cell Source and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase II drugs for Sickle Cell Disease have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Anti-Viral Central Memory CD8 Veto Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-Viral Central Memory CD8 Veto Cells overview
Cellular Immunotherapy is under development for the treatment of bone marrow transplantation under non-myeloablative conditioning in the absence of GvHD and organ transplantation with reduced incidence of viruses and sickle cell disease. The therapy is developed based on Anti 3rd Party Central Memory T cell (TCM) technology. It is a next generation T-cell therapy treatment targeting specific patient immune system characteristics. The therapy has direct cancer killing action.
Cell Source overview
Cell Source is a biotechnology company. It offers the development of cell therapy treatments based on the management of immune tolerance. The company’s Veto Cells are white blood cells taken from either the patient or a healthy third-party donor and used to prevent post-transplant infections resulting from common viruses that cause post-transplant complications and mortality. Cell Source also offers anti-rejection Veto Cell, Veto Cell genetically modified cells for allogeneic treatment and Veto Cell for non-malignant disease. The company patented Veto-Cell technology represents a breakthrough in immune system management safe and selective tolerizing of immune response, anti-rejection Veto Cells enable the selective attenuation of immune system response and others. The company provides revolutionizing transplantation and cancer treatment utilizing immune tolerance technology. Cell Source is headquartered in New York, the US.
For a complete picture of Anti-Viral Central Memory CD8 Veto Cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
